IL17A and viral hepatitis: Brodalumab was also well-tolerated by patients with a diagnosis of viral hepatitis, as repeated laboratory tests did not show transaminase elevations nor viral reactivation, consistent with data observed for other IL-17 and IL-23 inhibitors (25).